|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
12.70 Billion
|
|
CAGR
(2025-2030)
|
6.11%
|
|
Fastest
Growing Segment
|
Injectable
drug delivery
|
|
Largest
Market
|
West
India
|
|
Market
Size (2030)
|
USD
18.05 Billion
|
Market Overview
The India Drug Delivery Devices Market was valued at USD 12.70 billion in 2024 and is expected to reach USD 18.05 billion by 2030 with a CAGR of 6.11% during the forecast period.
The Drug Delivery Devices Market encompasses the global industry
dedicated to the development and sales of medical devices specifically designed
to deliver medications and therapeutic agents into the body in a controlled
manner. These devices play a crucial role in the treatment of a wide range of
illnesses and diseases, offering diverse options from simple syringe systems to cutting-edge nanotechnology. With various segments based on
the route of administration, including oral, injectable, topical, ocular,
nasal, and pulmonary, this market caters to the specific needs of patients
across different medical domains.
Technological advancements continue to drive
innovation in drug delivery devices, enabling more precise and targeted
treatment options for patients. The rising prevalence of chronic diseases and the growing geriatric population are significant factors driving this market's growth.
As demand for effective, convenient drug delivery solutions continues to rise, the Drug Delivery Devices Market remains a dynamic, evolving sector
within the healthcare industry.
Download Free Sample Report
Key Market Drivers
Rising
Prevalence of Chronic Diseases
India’s drug delivery devices market is gaining momentum as chronic disease management becomes a daily necessity, with non-communicable diseases causing 66 percent of all deaths in 2019 and diabetes already affecting 10.1 crore people, according to WHO-linked reporting and the ICMR INDIAB study cited by the Government of India. The pressure is amplified by India’s aging and respiratory burden, since COPD has become one of the country’s deadliest chronic conditions and the senior population is projected to reach 230 million by 2036, making insulin pens, inhalers, and other patient-friendly devices essential for accurate dosing, adherence, and home-based care.
This need is now translating into commercial opportunity in India’s insulin-delivery segment, where Novo Nordisk’s phased withdrawal of human insulin pens is expected to open a Rs 600 to 800 crore space for domestic players such as Eris Lifesciences, Lupin, and Wockhardt, underscoring how disease prevalence is directly shaping device demand rapidly.
Technological
Advancements in Medical Device Manufacturing
Technological innovation is reshaping India’s drug delivery devices landscape as manufacturers move toward smarter, more precise, and patient-centric formats that support long-term disease management across diabetes, respiratory care, and cardiovascular treatment. Connected insulin pens, advanced inhalation systems, drug-eluting platforms, and next-generation delivery technologies such as microneedles, liposomes, and nanoparticle-based systems are improving dose control and adherence while aligning with the country’s broader shift toward home-based and digitally enabled care.
This transition has gained additional traction through telemedicine, with the government’s eSanjeevani platform facilitating more than 33.8 crore consultations by January 2025, showing how remote care infrastructure is expanding the practical use case for self-administered and monitorable delivery devices across urban and underserved settings. On the manufacturing side, policy support is reinforcing this momentum, as India’s medical devices production push is backed by a Rs 3,420 crore PLI scheme and a separate Rs 500 crore scheme to strengthen the industry, creating a stronger domestic base for advanced delivery technologies.
Rapid
Growth of The Biopharmaceutical Industry
India’s biopharmaceutical expansion is steadily intensifying demand for advanced drug delivery devices, as the sector moves beyond conventional generics toward biologics, biosimilars, oncology therapies, and long-term chronic care products that depend on precise, stable, and patient-friendly administration formats such as prefilled injectors, wearable delivery systems, and specialty infusion solutions. This shift is closely tied to India’s broader biotechnology rise, with the country’s bioeconomy expanding from 10 billion dollars in 2014 to 165.7 billion dollars in 2024, while regulatory activity around complex biologics continues to deepen through approvals for products such as enfortumab vedotin, reinforcing the need for sophisticated delivery platforms that can support efficacy, safety, and adherence in real-world care settings. The commercial case is equally clear from industry scale, as Biocon reported FY25 revenue of Rs 16,470 crore and said four of its biosimilars each recorded sales of 200 million dollars, highlighting how India’s growing biologics base is creating sustained demand for high-performance injectable and device-enabled delivery technologies.
Rising
Investments by The Drug Manufacturers In The Clinical Trials
India’s expanding clinical research ecosystem is strengthening demand for advanced drug delivery devices as pharma companies bring more complex therapies into development and require inhalers, transdermal systems, injector platforms, and precision delivery formats that can improve usability, dosing accuracy, and patient adherence across trials and eventual commercial use.
The regulatory environment is also becoming more supportive of faster innovation, as the New Drugs and Clinical Trials Amendment Rules notified in January 2026 reduced the review timeline under Rule 53 from 90 working days to 45 working days, a shift that can accelerate development and validation of device-enabled therapies in India. A clear industry signal comes from Bristol Myers Squibb, which inaugurated a 100 million dollar Hyderabad facility expected to employ more than 1,500 people, while Reuters reported that its India unit was already participating in 17 clinical trials, underscoring how global investment is deepening the need for sophisticated delivery technologies within the country’s research pipeline.
Key Market Challenges
High
Risk of Needlestick Injuries
Despite the increased need for effective drug delivery devices in India, there is a growing concern over the high risk of needlestick injuries, which is negatively impacting the demand. Needlestick injuries pose a significant risk to
healthcare personnel, potentially leading to the transmission of blood-borne
pathogens, including HIV, Hepatitis B, and Hepatitis C. This risk factor is
especially relevant in a densely populated country like India, where the
healthcare system is often under pressure and safety protocols may not always
be strictly adhered to.
The fear of needlestick injuries is leading to a hesitancy in the adoption of
drug delivery devices, with many individuals preferring oral medication or
non-invasive treatment options instead. This shift in preference is disrupting market growth for drug delivery devices in India. To address
this ongoing issue, it is crucial to develop safer, more secure delivery systems that can regain consumer confidence and meet demand effectively. By
implementing advanced safety features and ensuring strict adherence to safety
protocols, the development of such delivery systems can mitigate the risks
associated with needlestick injuries. This, in turn, will help to restore
consumer trust and drive the demand for drug delivery devices in India.
Lack
of Awareness About Drug Delivery Devices
The
demand for Drug Delivery Devices (DDD) in India is currently experiencing a
significant downturn. This trend can be attributed to a general lack of
awareness about these devices, especially among people residing in rural and
semi-urban areas. Many individuals remain largely uninformed about the
existence, usage, and numerous benefits of DDDs.
These innovative devices are
specifically designed to deliver drugs into the human body in a controlled, precise manner, thereby enhancing the treatment of various medical conditions.
However, due to the absence of adequate knowledge and understanding, potential
users continue to rely on traditional methods of drug intake, which in turn
reduces the demand for sophisticated drug delivery systems. The problem is further compounded by inadequate marketing strategies and
insufficient training of healthcare professionals.
This lack of promotion and
education contributes to the prevailing unawareness surrounding DDDs. To
reverse this concerning trend, it is crucial to initiate extensive awareness
campaigns about DDDs, targeting both consumers and healthcare providers. These
campaigns should emphasize the immense benefits of using these devices for
effective drug administration, ensuring that individuals are well-informed and
empowered to make informed decisions about their healthcare. By increasing
awareness and understanding, we can pave the way for a greater adoption of DDDs
and improve the overall quality of healthcare delivery in India.
Key Market Trends
Increasing Funding from the Government & Private Organizations
Funding support from both the government and private sector is accelerating demand for drug delivery devices in India, as healthcare systems increasingly prioritize technologies that improve dosing accuracy, treatment adherence, and decentralized care across diabetes, respiratory disorders, oncology, and other chronic conditions. Public policy remains a major catalyst, with the Union Budget 2024 to 2025 raising the Ministry of Health and Family Welfare allocation to Rs 89,287 crore and the PRIP scheme adding a Rs 5,000 crore innovation outlay to strengthen research and commercialization in pharma and MedTech, including medical devices.
This financing push is being translated into wider care access through Ayushman Bharat, under which 1,81,873 Ayushman Arogya Mandirs were operational by November 2025 with an expanded package of 12 services, creating a larger delivery network for self-administered and facility-based drug delivery solutions. Private capital is reinforcing this ecosystem as TPG acquired a 35 percent stake in SCHOTT Poonawalla, a Serum Institute-linked injectable packaging and delivery platform that serves over 100 pharmaceutical customers and operates three manufacturing facilities in India with capacity above 3 billion units annually..
Innovative
Strategies Adopted by The Key Market Players
Innovative strategies by leading companies are materially strengthening demand for drug delivery devices in India, as manufacturers expand beyond conventional formats into drug eluting stents, insulin pens, connected glucose-linked systems, and other patient-centric technologies designed to improve dosing precision, ease of use, and long-term therapy adherence across cardiovascular and diabetes care. A major shift is now coming from digitized care models, where device makers are combining therapy delivery with data visibility, remote tracking, and app-based monitoring so that clinicians can intervene earlier and patients can manage treatment more confidently even outside hospital settings.
Abbott offers a clear example of this direction, having launched FreeStyle Libre 2 Plus in India with automatic glucose readings every minute delivered to smartphones, while stating that its FreeStyle Libre platform is already used by more than seven million people globally, highlighting how large companies are scaling connected care technologies that can widen access and reinforce trust in self-managed treatment pathways. This innovation-led expansion is helping extend advanced drug delivery solutions into broader clinical and consumer settings across the country.
Segmental Insights
Route of Administration Insights
Based on the Route of Administration, the Injectable drug delivery emerged as the fastest-growing segment in the Indian market for Drug Delivery Devices during the forecast period. Chronic diseases such as diabetes, cancer, autoimmune disorders, and cardiovascular conditions are increasingly prevalent in India. These conditions often necessitate long-term management with medications that are unsuitable for oral administration due to factors such as low bioavailability or gastrointestinal degradation. A growing number of biologic therapies, including monoclonal antibodies, insulin, and vaccines, require injectable delivery to ensure their effectiveness. These therapies have significantly advanced the treatment of chronic diseases and are increasingly being adopted in India.
The introduction of user-friendly self-injection devices, such as pen injectors and auto-injectors, has made injectable treatments more accessible, enabling patients to administer their own medications at home and improving compliance and convenience. For instance, insulin pens have become increasingly popular among patients with diabetes. Additionally, innovations such as needle-free injectors that use high pressure to deliver medication through the skin are helping mitigate discomfort and fear associated with injections, driving greater acceptance.
Injectable drugs offer more targeted delivery, directly administering the medication to the bloodstream or specific areas in the body, which is especially beneficial for localized treatments such as cancer or rheumatoid arthritis. Furthermore, controlled-release formulations allow for the gradual release of drugs, reducing the need for frequent dosing and enhancing patient compliance. There is a growing trend toward personalized medicine and the use of biologic therapies, which often require injectable delivery. Injectable medications often require fewer doses or are available in sustained-release formulations, which can improve patient compliance and lead to better health outcomes for chronic conditions. As India’s pharmaceutical market continues to expand, many companies are focusing on injectable formulations to meet both domestic and international demand. India’s emerging role as a manufacturing hub for biologics and injectables has further expanded the market for these products.
Application Insights
Based on application, diabetes emerged as the dominating segment in the Indian market for Drug Delivery Devices in 2024. This is due to the
sustained rise in population, coupled with improvements in healthcare
infrastructure and accessibility, which has led to a larger pool of individuals
seeking medical attention and preventive measures. This demographic shift
underscores the importance of addressing chronic conditions like diabetes,
which require ongoing management and treatment. The increasing disposable
income among consumers has enabled greater spending on healthcare and wellness
products.
As people prioritize their health and well-being, they are more
inclined to invest in technologies and solutions that help manage chronic diseases such as diabetes effectively. This trend is particularly
evident in emerging economies where rising affluence is translating into
greater healthcare expenditure. The sustained growth trajectory of the diabetes
segment underscores the pressing need to address diabetes as a public health
priority. Governments, healthcare providers, and industry stakeholders are
recognizing the importance of investing in preventive measures, early
diagnosis, and effective management strategies to mitigate the burden of
diabetes on individuals and healthcare systems alike.
Download Free Sample Report
Regional Insights
Based on region, West India emerged as the dominating region in the India Drug Delivery
Devices Market in 2024. This dominance can be attributed to the high concentration of
reputable pharmaceutical companies, supported by a robust healthcare
infrastructure and substantial investments in cutting-edge research and
development activities within these states.
The region's strategic
geographical location, favorable government policies, and well-established
supply chain networks contribute significantly to its prominence in the market.
In Maharashtra, for example, the city of Mumbai serves as a key hub for
pharmaceutical manufacturing and research, housing numerous renowned
pharmaceutical companies and research institutions. The state's well-developed
healthcare infrastructure, with top-notch hospitals and medical facilities, creates a conducive environment for the development and adoption of advanced drug-delivery devices.
Gujarat,
on the other hand, boasts a strong pharmaceutical presence with a wide range of
pharmaceutical companies operating in the state. The government's proactive
approach to promoting research and development, along with attractive incentives for pharmaceutical companies, has further bolstered the state's position as a major player in the drug-delivery devices market. The Western
region's strategic geographical location plays a crucial role in its prominence
within the market.
Situated on the western coast of India, it provides
convenient access to both domestic and international markets, facilitating
efficient distribution and export of drug delivery devices. The
region benefits from well-established supply chain networks, ensuring the smooth, timely delivery of products to healthcare providers and end users.
Recent Development
- In February 2026, Zydus Lifesciences said it would launch generic semaglutide in India with a novel 15 mg reusable multi-dose pen, to be sold under the brands Semaglyn, Mashema, and Altreme. The Economic Times report noted that the company positioned the device as a first-of-its-kind drug delivery mechanism in India, designed to simplify dose titration and reduce the need for multiple single-dose pens, which makes the launch significant as both a product introduction and a delivery-device innovation.
- In March 2026, Dr. Reddy’s Laboratories launched Obeda, described by The Economic Times as India’s first DCGI-approved semaglutide injection for Type 2 diabetes by an Indian company. The report said the drug’s development and manufacturing, including the API and formulation, were carried out in-house, and the launch stands out because it reflects Indian companies moving deeper into complex injectable therapies where the delivery format is central to patient adoption and differentiation.
- In March 2026, Zydus Lifesciences and Lupin entered into a licensing and supply agreement to expand access to semaglutide injection in India using a patient-friendly reusable pen device. According to the Economic Times coverage, the collaboration combines Zydus’ product and delivery-device platform with Lupin’s market reach, making it an important example of how partnerships are being used to scale advanced self-administration devices in India’s cardio-metabolic therapy segment.
- In December 2025, Cipla launched Afrezza in India, an orally inhaled insulin powder delivered through an inhaler device, giving diabetes patients a needle-free alternative to injectable insulin therapy. The ET Manufacturing report said Cipla had received regulatory approval from CDSCO for the exclusive distribution and marketing of the product, and highlighted that Afrezza uses single-use cartridges loaded into an inhaler, making this a notable drug-device introduction in India’s diabetes care market.
Key Market Players
- Pfizer Ltd.
- Novartis India Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- India Medtronic Private Ltd.
- Cardinal Health International India Pvt Ltd.
- B. Braun Medical (India) Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- 3M India Ltd.
- Cipla Ltd.
- Bayer Zydus Pharma
|
By
Devices
|
By
Route of Administration
|
By
Application
|
By
End User
|
By Region
|
|
Syringe
Inhaler
Nebulizer
Transdermal Patch
|
Oral Drug Delivery
Injectable Drug
Delivery
Topical Drug
Delivery
Others
|
Cancer
Respiratory Diseases
Diabetes
Cardiovascular Diseases
Others
|
Hospitals
Diagnostic Centres
Ambulatory Surgery Centres
Others
|
West
North
South
East
|
Report
Scope:
In
this report, the India Drug Delivery Devices Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- India Drug Delivery Devices Market, By Devices:
o
Syringe
o
Inhaler
o
Nebulizer
o
Transdermal Patch
- India Drug Delivery Devices Market, By Route of Administration:
o
Oral Drug Delivery
o
Injectable Drug Delivery
o
Topical Drug Delivery
o
Others
- India Drug Delivery Devices Market, By Application:
o
Cancer
o
Respiratory Diseases
o
Diabetes
o
Cardiovascular Diseases
o
Others
- India Drug Delivery Devices Market, By End User:
o
Hospitals
o
Diagnostic Centres
o
Ambulatory Surgery Centres
o
Others
- India Drug Delivery Devices Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Drug Delivery Devices
Market.
Available
Customizations:
India
Drug Delivery Devices Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India
Drug Delivery Devices Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]